Cardiac events after using clarithromycin for anti-Helicobacter pylori therapy in patients with coronary artery...

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Clarithromycin is a common antibiotic for H. pylori infections.
• The FDA recommends caution when prescribing clarithromycin to cardiac patients.
• Coronary artery disease (CAD) patients may have increased cardiac event risk.

Purpose of the Study:

• To evaluate cardiac events in CAD patients after H. pylori treatment.
• To assess the safety of clarithromycin in this patient group.

Main Methods:

• Retrospective 5-year study of outpatients receiving H. pylori therapy.
• Analysis of 7855 patients, with 228 diagnosed with CAD prior to therapy.
• Comparison of cardiac events between clarithromycin users (193 patients) and non-users.

Main Results:

• No significant difference in cardiac events at 3 months (4.7% vs 2.9%) or 1 year (10.9% vs 5.7%) between clarithromycin users and non-users.
• No life-threatening dysrhythmia or cardiac death observed.
• Smoking and diabetes mellitus identified as risk factors for cardiac events within 1 year.

Conclusions:

• Short-term cardiac events did not increase in CAD patients using clarithromycin for H. pylori therapy.
• Diabetes and smoking are significant risk factors for cardiac events in this population.
• Clarithromycin appears safe for H. pylori treatment in CAD patients, but risk factors require consideration.